Hyperlipidemia after allogeneic stem cell transplantation: prevalence, risk factors, and impact on prognosis

被引:21
作者
Kagoya, Yuki
Seo, Sachiko
Nannya, Yasuhito
Kurokawa, Mineo [1 ,2 ]
机构
[1] Univ Tokyo, Dept Hematol & Oncol, Grad Sch Med, Bunkyo Ku, Tokyo 1138655, Japan
[2] Tokyo Univ Hosp, Dept Cell Therapy & Transplantat Med, Tokyo 113, Japan
关键词
chronic graft-versus host disease; hematopoietic stem cell transplantation; hypercholesterolemia; hyperlipidemia; hypertriglyceridemia; VERSUS-HOST-DISEASE; LONG-TERM SURVIVORS; METABOLIC SYNDROME; LIPOPROTEIN-X; HYPERCHOLESTEROLEMIA; DYSLIPIDEMIA; LEUKEMIA;
D O I
10.1111/j.1399-0012.2012.01628.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Hyperlipidemia is one of the late complications after allogeneic stem cell transplantation (SCT). Although intrahepatic cholestasis caused by chronic graft-versus-host disease (GVHD) or calcineurin inhibitors has been considered as possible etiologies, its prevalence, risk factors, and impact on prognosis have not been investigated well. We performed a retrospective analysis of 194 patients who underwent allogeneic SCT between 1995 and 2008 in our institute and survived more than 100 similar to d after SCT. Overall, 83 (42.8%) and 99 (50.8%) patients developed hypercholesterolemia (=240 similar to mg/dL) and hypertriglyceridemia (=200 similar to mg/dL), respectively. In multivariate analysis, the development of chronic GVHD (hazard ratio [HR] 2.04, p similar to<similar to 0.05) and steroid use (HR 2.24, p similar to<similar to 0.01) were independently associated with hypercholesterolemia, while administration of calcineurin inhibitors was not. As for the prognostic impact, multivariate analysis showed that the patients with hypercholesterolemia had a tendency of lower rate of relapse (HR: 0.44, p similar to=similar to 0.07). There was no difference in non-relapse mortality or overall survival between the groups. In conclusion, the development of hypercholesterolemia is regarded as one of the symptoms accompanied with chronic GVHD and might indicate a better control of the primary disease.
引用
收藏
页码:E168 / E175
页数:8
相关论文
共 26 条
[1]   Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens [J].
Abou-Mourad, Y. R. ;
Lau, B. C. ;
Barnett, M. J. ;
Forrest, D. L. ;
Hogge, D. E. ;
Nantel, S. H. ;
Nevill, T. J. ;
Shepherd, J. D. ;
Smith, C. A. ;
Song, K. W. ;
Sutherland, H. J. ;
Toze, C. L. ;
Lavoie, J. C. .
BONE MARROW TRANSPLANTATION, 2010, 45 (02) :295-302
[2]   Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation [J].
Annaloro, C. ;
Usardi, P. ;
Airaghi, L. ;
Giunta, V. ;
Forti, S. ;
Orsatti, A. ;
Baldini, M. ;
Delle Volpe, A. ;
Deliliers, G. Lambertenghi .
BONE MARROW TRANSPLANTATION, 2008, 41 (09) :797-804
[3]   Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study [J].
Baker, KS ;
Gurney, JG ;
Ness, KK ;
Bhatia, R ;
Forman, SJ ;
Francisco, L ;
McGlave, PB ;
Robison, LL ;
Snyder, DS ;
Weisdorf, DJ ;
Bhatia, S .
BLOOD, 2004, 104 (06) :1898-1906
[4]   Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study [J].
Bhatia, Smita ;
Francisco, Liton ;
Carter, Andrea ;
Sun, Can-Lan ;
Baker, K. Scoff ;
Gurney, James G. ;
McGlave, Philip B. ;
Nademanee, Auayporn ;
O'Donnell, Margaret ;
Ramsay, Norma K. C. ;
Robison, Leslie L. ;
Snyder, David ;
Stein, Anthony ;
Forman, Stephen J. ;
Weisdorf, Daniel J. .
BLOOD, 2007, 110 (10) :3784-3792
[5]   Medical progress: Hematopoietic stem-cell transplantation [J].
Copelan, EA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (17) :1813-1826
[6]   National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report [J].
Filipovich, AH ;
Weisdorf, D ;
Pavletic, S ;
Socie, G ;
Wingard, JR ;
Lee, SJ ;
Martin, P ;
Chien, J ;
Przepiorka, D ;
Couriel, D ;
Cowen, EW ;
Dinndorf, P ;
Farrell, A ;
Hartzman, R ;
Henslee-Downey, J ;
Jacobsohn, D ;
McDonald, G ;
Mittleman, B ;
Rizzo, JD ;
Robinson, M ;
Schubert, M ;
Schultz, K ;
Shulman, H ;
Turner, M ;
Vogelsang, G ;
Flowers, MED .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (12) :945-956
[7]   Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management [J].
Griffith, Michelle L. ;
Savani, Bipin N. ;
Boord, Jeffrey B. .
BLOOD, 2010, 116 (08) :1197-1204
[8]   Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report [J].
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, R ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Cleeman, JI ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ ;
Keller, SA ;
Jehle, AJ .
CIRCULATION, 2002, 106 (25) :3143-3421
[9]   Fewer relapses and increased chronic GVHD in patients transplanted with blood stem cells: a 5-year follow-up in a single centre study [J].
Heldal, D ;
Brinch, L ;
Tjonnfjord, G ;
Solheim, BG ;
Egeland, T ;
Albrechtsen, D ;
Aamodt, G ;
Evensen, SA .
BONE MARROW TRANSPLANTATION, 2003, 32 (03) :257-264
[10]  
KUSTER GM, 1994, TRANSPLANTATION, V57, P1479